AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
Executive summary: AbbVie submitted a regulatory application to the European Medicines Agency for subcutaneous induction of risankizumab (SKYRIZI) in adults with moderate to severe active Crohn's disease, based on Phase 3 AFFIRM study data. Approval would provide a new, less invasive induction option for Crohn’s patients and expand the label for risankizumab, likely increasing AbbVie’s immunology sales.
Who is involved: AbbVie (sponsor), the European Medicines Agency (regulator), and investigators from the Phase 3 AFFIRM trial.
Likely next (inference): The EMA will launch a centralized review, with a CHMP opinion expected within about 12 months, followed by a possible European Commission decision.
AbbVie has submitted a marketing authorization application to the European Medicines Agency for the subcutaneous induction formulation of risankizumab (SKYRIZI) in adults with moderate to severe active Crohn's disease. The filing relies on data from the Phase 3 AFFIRM study, which demonstrated efficacy and safety comparable to the existing intravenous induction regimen. If approved, the new indication would offer patients a less invasive dosing option and broaden the therapeutic use of risankizumab, potentially strengthening AbbVie’s position in the immunology market.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Seamless Market Expansion (Base Case) (60%)
AbbVie captures immediate market share in the subcutaneous Crohn's segment, offsetting potential biosimilar erosion in older immunology assets.
- EMA grants marketing authorization for subcutaneous risankizumab
- Positive reimbursement negotiations with major EU member states
Regulatory Delay or Request for Information (Downside) (25%)
Delayed revenue ramp-up and increased short-term R&D scrutiny on the SKYRIZI franchise.
- EMA issues a list of questions (LoQ) regarding the AFFIRM study data
- Extension of the EMA review timeline beyond the standard timeframe
Clinical/Safety Divergence (Tail Risk) (15%)
Significant loss of confidence in the subcutaneous transition, impacting the entire IL-23 inhibitor portfolio.
- EMA issues a negative opinion based on safety profile concerns
- Post-marketing surveillance reports unexpected adverse events unique to subcutaneous delivery
What to watch
- EMA Committee for Medicinal Products for Human Use (CHMP) opinion release (Next 60-90 days)
- AbbVie quarterly guidance updates regarding immunology revenue growth
- European medical society congress publications on subcutaneous vs IV efficacy
Timeline
- — AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease (PR Newswire)
Analysis — what this means
Sectors affected
- immunology
- gastroenterology
- biopharmaceuticals
Historical parallels
- AbbVie’s Humira replacement strategy reported 2026-08-24
- AbbVie presented new data at WCLC 2026 on 2026-08-21
Key entities
Sources
Related cases
- Genmab and AbbVie demonstrate significant clinical improvement in DLBCL patients using Epcoritamab combined with R-CHOP
- AbbVie's Phase 2 trial shows its experimental drug zumilokibart significantly improves eczema symptoms versus placebo, advancing a potential new atopic dermatitis therapy
- Pharma deal volume jumps 70% to €343.5bn Jan‑Jul 2026, led by Lilly, BMS, AbbVie and GSK
- AbbVie’s neuroscience division is projected to generate $12.7 billion in sales this year, marking a key shift away from its Humira‑centric model
- Patent expirations on blockbuster drugs threaten $440 billion in pharma revenues, with Merck-MSD and AbbVie most exposed
- EMA PRIME designation accelerates AbelZeta's lupus therapy C-CAR168 toward faster regulatory approval and market entry